Anti-klrg1 antibodies
AssigneeAbcuro, Inc.
InventorsStefano V. GULLA, Kenneth Evan THOMPSON
Life of this patent
Estimating the term…
Abstract
The disclosure relates to antibodies, or antigen-binding fragments thereof, that specifically bind to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes, including treatment of cancers and to increase the effectiveness of vaccines.
Claims24
An antibody, or antigen-binding fragment thereof, that specifically binds to an extracellular domain of KLRG1 which comprises a heavy chain variable region comprising SEQ ID NO:
- 4.
An antibody, or antigen-binding fragment thereof, that specifically binds to an extracellular domain of KLRG1, which comprises a light chain variable region comprising SEQ ID NO:
- 5.
An antibody, or antigen-binding fragment thereof, that specifically binds to an extracellular domain of KLRG1which comprises:
- (a) a heavy chain variable region comprising SEQ ID NO:
- 4, and
- (b) a light chain variable region comprising SEQ ID NO:
- 5.
An antibody, or antigen-binding fragment thereof, that specifically binds to an extracellular domain of KLRG1, and which comprises a heavy chain comprising SEQ ID NO:
- 8.
An antibody, or antigen-binding fragment thereof, that specifically binds to an extracellular domain of KLRG1, and which comprises a light chain comprising SEQ ID NO:
- 9.
An antibody, or antigen-binding fragment thereof, that specifically binds to an extracellular domain of KLRG1, and which comprises:
- (a) a heavy chain comprising SEQ ID NO:
- 8, and
- (b) a light chain comprising SEQ ID NO:
- 9.
Dependencies are inferred from the claim text.